# Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of ASP2215 in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia

> **NCT02181660** · PHASE1 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 24 (actual)

## Conditions studied

- Acute Myeloid Leukemia (AML)

## Interventions

- **DRUG:** Gilteritinib

## Key facts

- **NCT ID:** NCT02181660
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06-16
- **Primary completion:** 2016-06-27
- **Final completion:** 2016-06-27
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2024-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02181660

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02181660, "Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of ASP2215 in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT02181660. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*